Immunization with a poly (lactide co-glycolide) encapsulated plasmid DNA expressing antigenic regions of HPV 16 and 18 results in an increase in the precursor frequency of T cells that respond to epitopes from HPV 16, 18, 6 and 11

Matijevic, Mark; Hedley, Mary Lynne; Urban, Robert G.; Chicz, Roman M.; Lajoie, Christa; Luby, Thomas M.

doi:10.1016/j.cellimm.2011.04.005

Cited by 44 publications

(25 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some of the peptides predicted in the study were already reported as CTL epitopes. HPV 16 peptides E1-LLQQYCLYL254-262 [34], E5-FLLCFCVLL15-23, VLLCVCLLI21-29 [35], E6-KLPQLCTEL18-26 [36,37] and E7-TLHEYMLDL7-15 [38] are known CTL epitopes. E7-LLMGTLGIV82-90 was known to induce the cellular response in HLA A2.1 rabbit model [39] and reduced tumor burden in aged mice [40].…”

Section: Discussionmentioning

confidence: 99%

Genome-Wide Prediction of Human Papilloma Virus Specific T-Cell Epitopes Using a Combination of Matrix Based Computational Tools

Mohan

Sundar

2017

Int J Pharm Pharm Sci

View full text Add to dashboard Cite

Objective: To predict the immunogenic epitopes from human papillomavirus (HPV) virus using matrix based computational tools. Methods:In the present study, three matrix based algorithms, SYFPETHI, BIMAS and RANKPEP were used to predict the cytotoxic T lymphocyte (CTL) epitopes of HPV 16 and 18. The ability of the peptides to bind HLA A_0201, a most common allele, was evaluated using these algorithms. High scoring peptides were considered as potential binders.Results: Evaluation of HPV 16 proteome resulted in the prediction of 249 peptides as potential binders. Out of these only 25 peptides were predicted as binders by all three algorithms. Analysis of HPV 18 predicted 215 peptides, as potential binders. Among the 215 peptides only 20 peptides were predicted as binders by all three algorithms. Conclusion:The efficacy of these peptides in inducing a stronger immune response needs to be tested using in vitro and in vivo assays. The identified epitopes could be used in designing a novel epitope vaccine for HPV.

show abstract

Section: Discussionmentioning

confidence: 99%

Genome-Wide Prediction of Human Papilloma Virus Specific T-Cell Epitopes Using a Combination of Matrix Based Computational Tools

Mohan

Sundar

2017

Int J Pharm Pharm Sci

View full text Add to dashboard Cite

show abstract

“…57 One of the rare nucleic acid vaccine therapies to a Phase II/III study incudes ZYC101a, an HPV-16 E7 HLA-A2 restricted peptide, which also encodes segments of HPV-16 and HPV-18 E6 and E7 viral proteins. 60,61 In a Phase II study of 21 patients receiving the vaccine, 11 had elevated CD8 þ T-cell responses to HPV-16 and/or HPV-18 peptides, and 7 of these also had increases to corresponding HPV-6 and/or HPV-11 peptides. In addition, T cells primed and expanded in vitro with an HPV-18 peptide had cross-reactivity to the corresponding HPV-11 peptide.…”

Section: Nucleic Acid-based Vaccinesmentioning

confidence: 99%

Immunotherapy: An Evolving Paradigm in the Treatment of Advanced Cervical Cancer

Eskander

Tewari

2015

Clinical Therapeutics

View full text Add to dashboard Cite

Purpose: In 2014, the US Food and Drug Administration approved the first targeted agent, bevacizumab, in the treatment of advanced stage, persistent, or recurrent cervical cancer. This oncologic milestone has catalyzed interest in the investigation of alternate therapies, including immunotherapy, in an effort to extend life and possibly cure patients with advanced stage disease.Methods: This review article focuses on the evolving paradigm of immunotherapy in the treatment of cervical cancer, describing the biologic basis of this treatment modality and discussing applicable Phase I to II clinical trials.Findings: To date several trials have been conducted exploring vaccine-based therapies, adoptive T-cell therapy, and immune-modulating agents in patients with cervical cancer with promising results.Implications: Immunotherapy represents a promising therapeutic paradigm in the treatment of advanced cervical cancer. Additional investigation is warranted to try and identify alternate immune targets and predictors of response, allowing for the selection of patients most likely to benefit from immune-based treatments. (Clin Ther. 2015;37:20-38) & 2015 Elsevier HS Journals, Inc. All rights reserved.

show abstract

“…Another DNA preparation (Amolimogene) contains an encapsulated plasmid encoding some proteins of HPV. In a small group of patients with HPV-associated high-grade CIN, no correlation between cellular immunity and clinical response was reported [110]. Another DNA preparation (Sig-E7(detox)-HSP70) encoding a fusion protein between HPV E7 protein and heat shock protein 70 was tried in a small group of patients with HPV-induced CIN 2/3.…”

Section: Dna-based Vaccinesmentioning

confidence: 99%

Prophylactic and Therapeutic Vaccines against Human Papillomavirus Infections

Rosales¹,

Rosales²

2017

Vaccines

View full text Add to dashboard Cite

Human papillomaviruses (HPVs) are a large family of double-strand DNA viruses comprising more than 180 types. Infection with HPV is associated with benign and malignant proliferation of skin and mucosae. Low-risk HPVs produce warts, whereas high-risk viruses induce tumors. Because there are no anti-viral drugs for HPV infection, there is a lot of interest in vaccines that can prevent the infection and also in vaccines that can be used to treat established infections and HPV-related tumors. Two prophylactic vaccines have been approved for preventing HPV infection. They seem to be efective when very young people are vaccinated. Unfortunately, many older people are still at risk of infection, mainly in countries where vaccination coverage is not eicient and for those people, novel therapeutic vaccines are being developed. This chapter describes the properties of HPV vaccines used today and the current status of several therapeutic vaccines been developed to treat HPV-induced lesions.

show abstract

Immunization with a poly (lactide co-glycolide) encapsulated plasmid DNA expressing antigenic regions of HPV 16 and 18 results in an increase in the precursor frequency of T cells that respond to epitopes from HPV 16, 18, 6 and 11

Cited by 44 publications

References 34 publications

Genome-Wide Prediction of Human Papilloma Virus Specific T-Cell Epitopes Using a Combination of Matrix Based Computational Tools

Genome-Wide Prediction of Human Papilloma Virus Specific T-Cell Epitopes Using a Combination of Matrix Based Computational Tools

Immunotherapy: An Evolving Paradigm in the Treatment of Advanced Cervical Cancer

Prophylactic and Therapeutic Vaccines against Human Papillomavirus Infections

Contact Info

Product

Resources

About